Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer

BJU International

Volumn 110, Issue 8, 2012, Pages 1149-1155

  Kijima, Toshiki ^a   Fujii, Yasuhisa ^a   Yokoyama, Minato ^a   Ishioka, Junichiro ^a   Matsuoka, Yoh ^a   Numao, Noboru ^a   Saito, Kazutaka ^a   Koga, Fumitaka ^a   Masuda, Hitoshi ^a   Kawakami, Satoru ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

anti androgen; castration resistant prostate cancer; deferred combined androgen blockade therapy; docetaxel; oestrogen

Indexed keywords

BICALUTAMIDE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; FOSFESTROL; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN; NITRILE; TAXOID; TOLUENESULFONIC ACID DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SPECIFIC SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; ESTROGEN THERAPY; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; VISCERAL METASTASIS; BLOOD; DRUG RESISTANCE; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; ESTROGENS; HUMANS; MALE; MIDDLE AGED; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS; TOSYL COMPOUNDS;

EID: 84871886652     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.10959.x     Document Type: Article

References (38)

1. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000; 355: 1491-8
2. Antonarakis ES, Eisenberger MA,. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011; 364: 2055-8
3. Tomlins SA, Mehra R, Rhodes DR, et al,. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39: 41-51
4. Chen CD, Welsbie DS, Tran C, et al,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-9
5. Stanbrough M, Bubley GJ, Ross K, et al,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-25
6. Montgomery RB, Mostaghel EA, Vessella R, et al,. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-54
7. Schmitt B, Wilt TJ, Schellhammer PF, et al,. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001; 57: 727-32
8. Samson DJ, Seidenfeld J, Schmitt B, et al,. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95: 361-76
9. Loblaw DA, Mendelson DS, Talcott JA, et al,. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004; 22: 2927-41
10. Heidenreich A, Aus G, Bolla M, et al,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80
11. Mohler J, Bahnson RR, Boston B, et al,. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8: 162-200
12. Fowler JE Jr, Pandey P, Seaver LE, Feliz TP,. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995; 154: 448-53
13. Scher HI, Steineck G, Kelly WK,. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46: 142-8
14. Fossa SD, Slee PH, Brausi M, et al,. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001; 19: 62-71
15. Fujikawa K, Matsui Y, Fukuzawa S, Takeuchi H,. Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. Eur Urol 2000; 37: 218-22
16. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H,. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004; 171: 679-83
17. Fujii Y, Kawakami S, Masuda H, et al,. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy. BJU Int 2006; 97: 1184-9
18. Ryan CJ, Small EJ,. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology 2003; 62 (Suppl. 1): 87-94
19. de Bono JS, Logothetis CJ, Molina A, et al,. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
20. Scher HI, Halabi S, Tannock I, et al,. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59
21. Antonarakis ES, Armstrong AJ,. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2011; 14: 192-205
22. Koivisto P, Kononen J, Palmberg C, et al,. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314-9
23. Tamura K, Furihata M, Tsunoda T, et al,. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 2007; 67: 5117-25
24. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, Visakorpi T,. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 2000; 164: 1992-5
25. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ,. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998; 52: 257-60
26. Kitahara S, Yoshida K, Ishizaka K, et al,. Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist. Endocr J 1997; 44: 527-32
27. Pomerantz M, Manola J, Taplin ME, et al,. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol 2007; 177: 2146-50
28. Montgomery B, Nelson PS, Vessella R, Kalhorn T, Hess D, Corey E,. Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer. BMC Cancer 2010; 10: 244-50
29. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M,. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396-403
30. Febbo PG, Richie JP, George DJ, et al,. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005; 11: 5233-40
31. Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH,. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009; 69: 1579-85
32. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N,. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010; 70: 7992-8002
33. Seruga B, Ocana A, Tannock IF,. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011; 8: 12-23
34. Tannock IF, de Wit R, Berry WR, et al,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
35. Small EJ, Vogelzang NJ,. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997; 15: 382-8
36. Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K,. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 2006; 12: 3003-9
37. Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K,. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res 2006; 12: 6012-7
38. Scher HI, Beer TM, Higano CS, et al,. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46